Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00958
|
|||||
| Drug Name |
Raltitrexed
|
|||||
| Synonyms |
(2S)-2-[[5-[methyl-[(2-methyl-4-oxo-1H-quinazolin-6-yl)methyl]amino]thiophene-2-carbonyl]amino]pentanedioic acid; 112887-68-0; C21H22N4O6S; CHEBI:5847; CHEMBL225071; D 1694; D-1694; D1694; DSSTox_CID_26482; DSSTox_GSID_46482; DSSTox_RID_81653; FCB9EGG971; ICI D1694; ICI-D-1694; ICI-D1694; N-(5-(N-(3,4-Dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-N-methylamino)-2-thenoyl)-L-glutamic acid; NCGC00229704-01; NSC-639186; Raltitrexed (Tomudex); Tomudex; UNII-FCB9EGG971; ZD 1694; ZD-16; ZD-1694; ZD1694
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Rectal cancer [ICD11: 2B92] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H22N4O6S
|
|||||
| Canonical SMILES |
CC1=NC2=C(C=C(C=C2)CN(C)C3=CC=C(S3)C(=O)NC(CCC(=O)O)C(=O)O)C(=O)N1
|
|||||
| InChI |
InChI=1S/C21H22N4O6S/c1-11-22-14-4-3-12(9-13(14)19(28)23-11)10-25(2)17-7-6-16(32-17)20(29)24-15(21(30)31)5-8-18(26)27/h3-4,6-7,9,15H,5,8,10H2,1-2H3,(H,24,29)(H,26,27)(H,30,31)(H,22,23,28)/t15-/m0/s1
|
|||||
| InChIKey |
IVTVGDXNLFLDRM-HNNXBMFYSA-N
|
|||||
| CAS Number |
CAS 112887-68-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 458.5 | Topological Polar Surface Area | 177 | ||
| Heavy Atom Count | 32 | Rotatable Bond Count | 9 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
1.4
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:5847
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| MRP2 | Transporter Info | Multidrug resistance-associated protein 2 | Substrate | [3] | ||
| References | ||||||
| 1 | The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. (familyId=7403) | |||||
| 2 | Pharmacogenomic importance of ABCG2. Pharmacogenomics. 2008 Aug;9(8):1005-9. | |||||
| 3 | Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res. 1999 Jun 1;59(11):2532-5. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.